65,437 trials
Prostate Cancer
Primary: Objective Response Rate (ORR) Cohorts B and C Per BICR — 12.5; 20.0 Percent of Participants
Overweight · Obesity
Primary: Percent Change From Baseline in Body Weight (Primary Treatment Period) — -2.4; -16.0; -21.4; -22.5 percent change — p=<0.001
Xerostomia
Primary: Xerostomia One Month After Completion of Treatment — 5; 7; 1; 6 Participants
Suicide · Psychosis
Primary: Calgary Depression Rating Scale (CDRS) — 13.60; 9.00; 11.00; 7.60 score on a scale
Kidney Transplant Infection
Primary: Incidence of Cytomegalovirus Infection or Disease — 9; 7; 39 Participants
Sarcoma
Primary: Number of Patients With Abdominal Recurrence or Death — 72; 73; 61; 60 Participants — p=0.955
Acute Coronary Syndrome · Depression · Myocardial Infarction
Primary: Recruitment Feasibility: Percent of Participants Who Consent to Screening — 150 Participants
Fallopian Tube Cancer · Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Overall Response — 1; 1 Participants
Squamous Cell Carcinoma of the Oral Cavity
Primary: Area Under the Curve (AUC) for Matrine in Saliva — 4007.9 ng x h/mL
Glabellar Lines · Lateral Canthal Lines
Primary: The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) — 0; 78; 66 Participants
Cognitive Impairment · Malignant Neoplasm
Primary: Effects of Ibuprofen on Alleviating Chemotherapy-related Cognitive Impairment — 89.98; 91.08; 105.54; 107.75 score on a scale — p=0.7917
Critical Illness · Oncology · Communication
Primary: Acceptability of the Proposed Intervention According to a Structured Qualitative Survey of Caregivers — 9; 10; 1; 3 Participants
Moderate to Severe Asthma
Primary: Post-vaccination Strain-specific Hemagglutination Inhibition (HAI) Antibody Geometric Mean Fold Rises (GMFRs) — 7.34; 4.75; 1.76; 1.46 Fold change
Hearing Loss
Primary: Subjective Satisfaction of Hearing Aid Performance in Noisy Environments — 3.86 score on a scale
Urinary Bladder Neoplasms
Primary: Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03 — 15; 14; 20 Participants